复发/难治性急性淋巴细胞白血病患者经博纳吐单抗治疗失败后的结局:CD19表达水平无变化
该研究描述了68例复发/难治性B细胞急性淋巴细胞白血病患者在接受博纳吐单抗治疗失败后的结局,其中38例(56%)为博纳吐单抗难治,30例(44%)为初始缓解后复发。中位随访49个月后,9例(13%)患者仍存活,博纳吐单抗失败后的中位总生存期为5.2个月。在61例可评估免疫表型的患者中,56例(92%)为CD19阳性原始细胞,仅5例(8%)复发时为CD19阴性,2例CD19表达降低。
要点
- 博纳吐单抗失败后患者预后差,中位总生存期仅5.2个月。
- 博纳吐单抗失败时绝大多数(92%)患者CD19仍为阳性。
- 博纳吐单抗治疗不会排除后续CD19靶向治疗(如CAR-T)的可能。
核心结论
- 复发/难治性急性淋巴细胞白血病患者经博纳吐单抗治疗失败后结局不佳,治疗需求未满足。
- 博纳吐单抗治疗不会使大量患者失去后续CD19靶向治疗(如嵌合抗原受体T细胞治疗)的潜在获益机会。
研究设计与样本
- 研究描述了68例复发/难治性急性淋巴细胞白血病患者经博纳吐单抗治疗失败后的结局。
- 其中38例(56%)为博纳吐单抗难治,30例(44%)为初始缓解后复发。
主要发现
- 中位随访49个月后,9例(13%)患者仍存活。
- 博纳吐单抗失败后的中位总生存期为5.2个月。
- 在61例可评估免疫表型的患者中,56例(92%)为CD19阳性原始细胞,仅5例(8%)为CD19阴性复发。
- 2例患者CD19表达降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Blinatumomab, a bi-specific T-cell engaging CD3-CD19 antibody construct, has shown significant activity in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL). Despite this improvement, most patients relapse. Here, we describe the outcome of 68 patients with R/R ALL after failure of blinatumomab therapy: 38 (56%) blinatumomab refractory; 30 (44%) relapsing after initial response. After a median follow-up of 49 months, 9 (13%) patients remained alive. The median overall survival after blinatumomab failure was 5.2 months. At the time of failure, among 61 patients evaluated for immunophenotype, 56 (92%) had CD19-positive blasts; only five (8%) had ALL recurrence with CD19-negative disease. Two patients progressed with lower CD19 expression. In summary, the outcome of patients with R/R ALL after blinatumomab failure is poor and treatment of these patients remains an unmet medical need. Our findings indicate that blinatumomab therapy would not exclude a significant number of patients from the potential benefit of subsequent CD19-directed therapies such as chimeric antigen receptor T-cell therapy.
引用
- Jabbour E, Düll J, Yilmaz M, et al. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol. 2017. PMID: 29178361. doi:10.1002/ajh.24987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。